Kazuo Chijiiwa

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Mikio Kanemaru · 2 shared papers, 2012–2013 · strength 0.10
   • Paper Antiproliferative effect of 1α,25-dihydroxyvitamin D3 involves upregulation of cyclin-dependent kinase inhibitor p21 in… DOI 10.5754/hge11073↗
   • Paper Thrombin stimulates integrin β1-dependent adhesion of human pancreatic cancer cells to vitronectin through protease-act… DOI 10.5754/hge10036↗
2. Takeda Yasuo · 1 shared paper, 2015 · strength 0.04
   • Paper Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic … DOI 10.1016/j.jphs.2015.01.006↗
3. Kentaro Minami · 1 shared paper, 2015 · strength 0.04
   • Paper Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic … DOI 10.1016/j.jphs.2015.01.006↗
4. Taketo Yamaguchi · 1 shared paper, 2014 · strength 0.03
   • Paper Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and meta… DOI 10.1007/s00280-013-2323-6↗
5. Tetsuhiko Shirasaka · 1 shared paper, 2014 · strength 0.03
   • Paper Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and meta… DOI 10.1007/s00280-013-2323-6↗
6. Hiroaki Yanagimoto · 1 shared paper, 2014 · strength 0.03
   • Paper Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and meta… DOI 10.1007/s00280-013-2323-6↗
7. Sohei Satoi · 1 shared paper, 2014 · strength 0.03
   • Paper Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and meta… DOI 10.1007/s00280-013-2323-6↗
8. Shinichi Egawa · 1 shared paper, 2014 · strength 0.03
   • Paper Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and meta… DOI 10.1007/s00280-013-2323-6↗
9. Jun Kato · 1 shared paper, 2014 · strength 0.03
   • Paper Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and meta… DOI 10.1007/s00280-013-2323-6↗
10. Ken‐ichi Okada · 1 shared paper, 2014 · strength 0.03
    • Paper Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and meta… DOI 10.1007/s00280-013-2323-6↗
11. Hiroki Yamaue · 1 shared paper, 2014 · strength 0.03
    • Paper Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and meta… DOI 10.1007/s00280-013-2323-6↗
12. Motoki Miyazawa · 1 shared paper, 2014 · strength 0.03
    • Paper Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and meta… DOI 10.1007/s00280-013-2323-6↗
13. Seiko Hirono · 1 shared paper, 2014 · strength 0.03
    • Paper Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and meta… DOI 10.1007/s00280-013-2323-6↗
14. A‐Hon Kwon · 1 shared paper, 2014 · strength 0.03
    • Paper Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and meta… DOI 10.1007/s00280-013-2323-6↗
15. Masaji Tani · 1 shared paper, 2014 · strength 0.03
    • Paper Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and meta… DOI 10.1007/s00280-013-2323-6↗
16. Manabu Kawai · 1 shared paper, 2014 · strength 0.03
    • Paper Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and meta… DOI 10.1007/s00280-013-2323-6↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.